View More View Less
  • 1 Semmelweis Egyetem, Általános Orvostudományi Kar, Budapest, Szentkirályi u. 46., 1088
  • 2 Debreceni Egyetem, Általános Orvostudományi Kar, Debrecen
Open access

Absztrakt

Az intestinalis zsírsavkötő fehérje a zsírsavkötő fehérjék családjába tartozó, a vékony- és vastagbél enterocytáinak citoszoljában termelődő, kis molekulasúlyú fehérje. Az enterocytasejtek membránintegritásának megbomlását követően megjelenik a szisztémás keringésben, és a vesék glomerularis szűrőjén keresztül kiválasztódik a vizeletbe. A szerzők akut és krónikus enterocytakárosodással járó gastrointestinalis kórképekben az intestinalis zsírsavkötő fehérje biomarkerként való használatával kapcsolatos vizsgálatokat tekintik át. Orv. Hetil., 2016, 157(2), 59–64.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1

    Storch, J., Thumser, A. E.: The fatty acid transport function of fatty acid-binding proteins. Biochim. Biophys. Acta, 2000, 1486(1), 28–44.

  • 2

    Pelsers, M. M., Hermens, W. T., Glatz, J. F.: Fatty acid-binding proteins as plasma markers of tissue injury. Clin. Chim. Acta, 2005, 352(1–2), 15–35.

  • 3

    Schaap, F. G., van der Vusse, G. J., Glatz, J. F.: Evolution of the family of intracellular lipid binding proteins in vertebrates. Mol. Cell. Biochem., 2002, 239(1–2), 69–77.

  • 4

    Hermens, W. T.: Mechanisms of protein release from injured heart muscle. Dev. Cardiovasc. Med., 1998, 205, 85–98.

  • 5

    Pelsers, M. M., Namiot, Z., Kisielewski, W., et al.: Intestinal-type and liver-type fatty acid-binding protein in the intestine. Tissue distribution and clinical utility. Clin. Biochem., 2003, 36(7), 529–535.

  • 6

    Derikx, J. P., Vreugdenhil, A. C., Van den Neucker, A. M., et al.: A pilot study on the noninvasive evaluation of intestinal damage in celiac disease using I-FABP and L-FABP. J. Clin. Gastroenterol., 2009, 43(8), 727–733.

  • 7

    Levy, E., Ménard, D., Delvin, E., et al.: Localization, function and regulation of the two intestinal fatty acid-binding protein types. Histochem. Cell Biol., 2009, 132(3), 351–367.

  • 8

    Derikx, J. P., Evennett, N. J., Degraeuwe, P. L., et al.: Urine based detection of intestinal mucosal cell damage in neonates with suspected necrotising enterocolitis. Gut, 2007, 56(10), 1473–1475.

  • 9

    Lin, P. W., Stoll, B. J.: Necrotising enterocolitis. Lancet, 2006, 368(9543), 1271–1283.

  • 10

    Fanaroff, A. A., Korones, S. B., Wright, L. L., et al.: Incidence, presenting features, risk factors and significance of late onset septicemia in very low birth weight infants. The National Institute of Child Health and Human Development Neonatal Research Network. Paediatr. Infect. Dis. J., 1998, 17(7), 593–598.

  • 11

    Hällström, M., Koivisto, A., Janas, M., et al.: Laboratory parameters predictive of developing necrotizing enterocolitis in infants born before 33 weeks of gestation. J. Pediatr. Surg., 2006, 41(4), 792–798.

  • 12

    Lieberman, J. M., Sacchettini, J., Marks, C., et al.: Human intestinal fatty acid binding protein: Report of an assay with studies in normal volunteers and intestinal ischemia. Surgery, 1997, 121(3), 335–342.

  • 13

    Edelson, M. B., Sonnino, R. E., Bagwell, C. E., et al.: Plasma intestinal fatty acid binding protein in neonates with necrotizing enterocolitis: a pilot study. J. Pediatr. Surg., 1999, 34(10), 1453–1457.

  • 14

    Guthmann, F., Börchers, T., Wolfrum, C., et al.: Plasma concentration of intestinal- and liver-FABP in neonates suffering from necrotizing enterocolitis and in healthy preterm neonates. Mol. Cellular Biochem., 2002, 239(1–2), 227–234.

  • 15

    Thuijls, G., van Wijck, K., Grootjans, J., et al.: Early diagnosis of intestinal ischemia using urinary and plasma fatty acid binding proteins. Ann. Surg., 2011, 253(2), 303–308.

  • 16

    Aydemir, C., Dilli, D., Oguz, S. S., et al.: Serum intestinal fatty acid binding protein level for early diagnosis and prediction of severity of necrotizing enterocolitis. Early Hum. Dev., 2011, 87(10), 659–661.

  • 17

    Schurink, M., Kooi, E. M., Hulzebos, C. V., et al.: Intestinal fatty acid-binding protein as a diagnostic marker for complicated and uncomplicated necrotizing enterocolitis: a prospective cohort study. PLoS ONE, 2015, 10(3), e0121336.

  • 18

    Güzel, M., Sözüer, E. M., Salt, Ö., et al.: The value of the serum I-FABP level for diagnosing acute mesenteric ischemia. Surg. Today, 2014, 44(11), 2072–2076.

  • 19

    Matsumoto, S., Sekine, K., Funaoka, H., et al.: Diagnostic performance of plasma biomarkers in patients with acute intestinal ischaemia. Br. J. Surg., 2014, 101(3), 232–238.

  • 20

    Kanda, T., Fujii, H., Tani, T., et al.: Intestinal fatty acid-binding protein is a useful diagnostic marker for mesenteric infarction in humans. Gastroenterology, 1996, 110(2), 339–343.

  • 21

    Kanda, T., Tsukahara, A., Ueki, K., et al.: Diagnosis of ischemic small bowel disease by measurement of serum intestinal fatty acid binding protein in patients with acute abdomen: a multicenter, observer-blinded validation study. J. Gastroenterol., 2011, 46(4), 492–500.

  • 22

    Rosero, O., Ónody, P., Kovács, T., et al.: Impaired intestinal mucosal barrier upon ischemia-reperfusion: “Patching holes in the shield with a simple surgical method”. BioMed Res. Int., 2014, 2014, 210901.

  • 23

    Adriaanse, M. P., Tack, G. J., Passos, V. L., et al.: Serum I-FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies. Aliment. Pharmacol. Ther., 2013, 37(4), 482–490.

  • 24

    Rodríguez-Martín, L., Vaquero, L., Vivas, S.: Letter: serum I-FABP as marker for enterocyte damage in first-degree relatives of patients with coeliac disease. Aliment. Pharmacol. Ther., 2015, 42(1), 121–122.

  • 25

    Adriaanse, M. P., Buurman, W. A., Vreugdenhil, A. C.: Letter: serum I-FABP as marker for enterocyte damage in first-degree relatives of patients with coeliac disease – authors’ reply. Aliment. Pharmacol. Ther., 2015, 42(1), 122.

  • 26

    Sarikaya, M., Ergül, B., Doğan, Z., et al.: Intestinal fatty acid binding protein (I-FABP) as a promising test for Crohn’s disease: a preliminary study. Clin. Lab., 2015, 61(1–2), 87–91.

  • 27

    Wiercinska-Drapalo, A., Jaroszewicz, J., Siwak, E., et al.: Intestinal fatty acid binding protein (I-FABP) as a possible biomarker of ileitis in patients with ulcerative colitis. Regul. Pept., 2008, 147(1–3), 25–28.

  • 28

    Wiest, R., Lawson, M., Geuking, M.: Pathological bacterial translocation in liver cirrhosis. J. Hepatol., 2014, 60(1), 197–209.

  • 29

    Norman, K., Pirlich, M.: Gastrointestinal tract in liver disease: which organ is sick? Curr. Opin. Clin. Nutr. Metab. Care, 2008, 11(5), 613–619.

  • 30

    Saitoh, O., Sugi, K., Lojima, K., et al.: Increased prevalence of intestinal inflammation in patients with liver cirrhosis. World J. Gastroenterol., 1999, 5(5), 391–396.

  • 31

    De Palma, G. D., Rega, M., Masone, S., et al.: Mucosal abnormalities of the small bowel in patients with cirrhosis and portal hypertension: a capsule endoscopy study. Gastrointest. Endosc., 2005, 62(4), 529–534.

  • 32

    Bhonchal, S., Nain, C. K., Prasad, K. K., et al.: Functional and morphological alterations in small intestine mucosa of chronic alcoholics. J. Gastroenterol. Hepatol., 2008, 23(7 Pt 2), e43–e48.

  • 33

    Balzan, S., de Almeida Quadros, C., de Cleva, R., et al.: Bacterial translocation: overview of mechanisms and clinical impact. J. Gastroenterol. Hepatol., 2007, 22(4), 464–471.

  • 34

    Du Plessis, J., Vanheel, H., Janssen, C. E., et al.: Activated intestinal macrophages in patients with cirrhosis release NO and IL-6 that may disrupt intestinal barrier function. J. Hepatol., 2013, 58(6), 1125–1132.

  • 35

    Sandler, N. G., Koh, C., Roque, A., et al.: Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology, 2011, 141(4), 1220–1230.

  • 36

    Villa, E., Cammà, C., Marietta, M., et al.: Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology, 2012, 143(5), 1253–1260.

  • 37

    French, A. L., Evans, C. T., Agniel, D. M., et al.: Microbial translocation and liver disease progression in women coinfected with HIV and hepatitis C virus. J. Infect. Dis., 2013, 208(4), 679–689.